BMT is continuing to progress each business segment, with Saudi...

BMT is continuing to progress each business segment, with Saudi Arabia/PICQ clearly having great potential...but in the meantime, leveraging their partnership with Abbott, and expanding across EU, UK Canada, India and, of course, continuing to make progress in ANZ. Revenue growth running at c25% in Q1 on pcp and reaffirmed that they are on track to deliver an operating profit in F24. I like the fact that, as they focus on revenue growth, they remain vigilant on managing costs (collaboration, free carry on paid trials etc), and also continue to develop some really innovative products.
BMT now has a portfolio of really cutting edge, quality, revenue-generating products - particularly PICQ, RippleDown and ADI.
They haven't raised capital at the lows (hello Alcidion?) and I'm comfortable with the progress they have made to date. The journey to critical mass is always going to be a little volatile. Growing organically to achieve $60m by end 2026?....it's possible - consensus rev f/c's for F25 are around $50m, and about breakeven at the NPAT level, then, hopefully, should start to see the operating leverage kick in. All IMHO DYOR. Looking forward to seeing the product demo at 2pm.